Statistical Analyses
All analyses were descriptive and, unless otherwise specified, were conducted on the all-treated/safety population, which was defined as all patients who received at least one dose of study medication. The DLT-evaluable populations comprised all patients in cohort Q2W-LD who completed cycle 2 and who received at least 80% of the intended dose in the first two infusions and all patients in cohort Q3W who completed cycle 1 and who received at least 80% of the first infusion, unless the patient discontinued treatment because of a DLT.